Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Amgen
Woman and Man
Between 28 years and 18 years
Amgen
Update Il y a 4 ans
Étude 20120215 : étude de phase 3 randomisée visant à comparer l’efficacité, la sécurité et la tolérance du blinatumomab comme thérapie de consolidation à une chimiothérapie de consolidation conventionnelle chez des enfants ayant une leucémie aiguë lymphoblastique à précurseur B à haut risque de première rechute.
La leucémie aiguë lymphoblastique à précurseur des lymphocytes B est une maladie agressive, traité par des chimiothérapies combinées qui présentent une toxicité importante. Pour les patients qui rechu...
Country
France
organs
Leucémies aiguës
Specialty
Pédiatrie
,
Chimiothérapie
,
Immunothérapie - Vaccinothérapie
Essai ouvert aux inclusions
More information
Woman and Man Max 99 years
Amgen, Inc
Update Il y a 4 ans
A Study of the Effects of AMG 334 to Prevent Migraine Headaches
To evaluate the effect of AMG 334 compared to placebo on the change from baseline in monthly migraine days, in subjects with chronic migraine
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Amgen
Update Il y a 4 ans
Étude 20140286 : étude de phase 1b visant à évaluer la sécurité d’emploi et la pharmacocinétique du blinatumomab par voie sous-cutanée chez des patients ayant un lymphome non hodgkinien indolent en rechute ou réfractaire.
Le lymphome non hodgkinien est un cancer qui prend naissance à partir de cellules du système lymphatique, des lymphocytes, impliquées dans les réactions de défense de l’organisme. Le lymphome non hodg...
Country
France
organs
Lymphomes non hodgkinien
Specialty
Immunothérapie - Vaccinothérapie
Essai ouvert aux inclusions
More information
Woman and Man
Between 18 years
and 99 years
Amgen
Update Il y a 4 ans
Étude 20130232 : étude de phase 1-3, randomisée, évaluant la tolérance et l’efficacité de l’association du Talimogene Laherparepvec et du pembrolizumab, chez des patients ayant un cancer de la tête et du cou récidivant ou métastatique. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
20130232 : Étude de phase 1b/3, multicentrique, randomisée, en ouvert, évaluant l’association du TVEC et du Pembrolizumab chez des patients présentant un carcinome épidermoïde de la tête et du cou réc...
Country
France
organs
Tête et cou
Specialty
Immunothérapie - Vaccinothérapie
Essai clos aux inclusions
More information
Woman and Man Max 99 years
KAI Pharmaceuticals, Inc. (a subsidiary of Amgen, Inc.)
Update Il y a 4 ans
A study of AMG 416 in the treatment of secondary hyperparathyroidism in chronic kidney disease
To characterize the long-term safety and tolerability of AMG 416 in the treatment of SHPT in subjects with chronic kidney disease on hemodialysis.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Amgen, Inc
Update Il y a 4 ans
Comparison of survival benefit of panitumumab with supportive care to best supportive care alone in patients with metastatic colorectal cancer
To evaluate the effect of panitumumab and best supportive care (BSC) versus BSC alone on overall survival (OS) in subjects with chemorefractory wild-type codons 12 and 13 Kirsten rat sarcoma viral onc...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Amgen, Inc
Update Il y a 4 ans
A Randomized Open-Label Study of Darbepoetin alfa Administered Every Three Weeks with or without Parenteral Iron in Anemic Subjects with Nonmyeloid Malignancies Receiving Chemotherapy
To compare hematopoietic response after 16 weeks of treatment with 500 mcg once every 3 weeks (Q3W) darbepoetin alfa and either IV iron or following standard practice (oral iron or no iron supplementa...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Amgen, Inc
Update Il y a 4 ans
Study designed to evaluate the safety and efficacy of AMG 145 compared with Ezetimibe treatment, in people with high cholesterol who have experienced side effects whilst taking existing statin treatment Studio per valutare l’efficacia e la sicurezza di AMG 145 rispetto rispetto al trattamento con ezetimibe, in soggetti con elevati livelli di colesterolo che hanno avuto effetti indesiderati durante il trattamento con statine
To evaluate the effect of AMG 145 administered subcutaneously (SC) once every month (QM) compared with ezetimibe (Part B), on percent change from baseline in low-density lipoprotein cholesterol (LDL-C...
Country
None
organs
None
Specialty
None
unknown
More information
Woman Max 99 years
Amgen, Inc
Update Il y a 4 ans
A study of AMG 386 or placebo in combination with paclitaxel and carboplatin to treat ovarian cancer Μια μελέτη με AMG 386 ή εικονικού φαρμάκου σε συνδυασμό με πακλιξατέλη και καρβοπλατίνη για τη θεραπεία του καρκίνου των ωοθηκών
To determine if 6 cycles of paclitaxel and carboplatin plus AMG 386 followed by 18 months of AMG 386 maintenance improves progression-free survival (PFS) compared to 6 cycles of paclitaxel and carbopl...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Amgen, Inc
Update Il y a 4 ans
Study to assess the safety and efficacy of AMG-145 in combination with Statin therapy in patients with high blood cholesterol or high concentration of lipids in the blood
To evaluate the effect of 12 weeks of subcutaneous (SC) AMG 145 administered every 2 weeks (Q2W) and monthly (QM) when used in combination with a statin, compared with placebo, on percent change from ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
1
2
3
4
5
6
7
8
9
10
Next